Evidence Construction of Chuankezhi Injection Against Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Pharmacology

IF 2.8 3区医学 Q1 Medicine

International Journal of Chronic Obstructive Pulmonary Disease Pub Date : 2024-05-27 DOI:10.2147/copd.s442281

Xuan Wei, Yu Zhong, Xiaofei Yi, Tingting Li, Zhougui Ling, Moyu Ming, Shuang Zhang, Zhiyi He

{"title":"Evidence Construction of Chuankezhi Injection Against Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Pharmacology","authors":"Xuan Wei, Yu Zhong, Xiaofei Yi, Tingting Li, Zhougui Ling, Moyu Ming, Shuang Zhang, Zhiyi He","doi":"10.2147/copd.s442281","DOIUrl":null,"url":null,"abstract":"Objective: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with high prevalence, morbidity, and mortality. Chuankezhi (CKZ) injection, a Chinese patent medicine, has been commonly used for treating COPD. This study evaluated the clinical efficacy of CKZ injections in COPD patients and explored potential underlying mechanisms by integrating meta-analysis and network pharmacology. Research Methods: Randomized controlled trials (RCTs) were search in database by Web of Science, Cochrane Library and PubMed as of November 2022 for literature collection, and the Review Manager 5.4 was used to analyze the data. Through the network pharmacology method, the chemical components and their targets, as well as the disease targets were further analyzed. Results: A total of 15 RCTs including 1212 patients were included. The results of meta-analysis showed that CKZ injection can significantly improve the clinical effective rate (RR = 1.25, 95% CI: 1.14 to 1.36), and the clinical advantage was that it can significantly reduced acute exacerbation rate (RR = 0.29, 95% CI: 0.12 to 0.70) and COPD assessment test (CAT) scores (MD =− 4.62, 95% CI:-8.966 to-0.28). A total of 31 chemical compounds and 178 potential targets for CKZ injection were obtained from the online databases. Molecular docking revealed that most key components and targets could form stable structure. Conclusion: This systematic review with meta-analysis and network pharmacology demonstrates that CKZ could effectively improve the clinical efficacy and safety in the treatment of COPD. Such efficacy may be related to an anti-inflammatory effect and immunoregulation of CKZ via multiple components, multiple targets and multiple pathways. Keywords: meta-analysis, network pharmacology, chronic obstructive pulmonary disease, Chuankezhi injection ","PeriodicalId":13792,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"63 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/copd.s442281","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with high prevalence, morbidity, and mortality. Chuankezhi (CKZ) injection, a Chinese patent medicine, has been commonly used for treating COPD. This study evaluated the clinical efficacy of CKZ injections in COPD patients and explored potential underlying mechanisms by integrating meta-analysis and network pharmacology.
Research Methods: Randomized controlled trials (RCTs) were search in database by Web of Science, Cochrane Library and PubMed as of November 2022 for literature collection, and the Review Manager 5.4 was used to analyze the data. Through the network pharmacology method, the chemical components and their targets, as well as the disease targets were further analyzed.
Results: A total of 15 RCTs including 1212 patients were included. The results of meta-analysis showed that CKZ injection can significantly improve the clinical effective rate (RR = 1.25, 95% CI: 1.14 to 1.36), and the clinical advantage was that it can significantly reduced acute exacerbation rate (RR = 0.29, 95% CI: 0.12 to 0.70) and COPD assessment test (CAT) scores (MD =− 4.62, 95% CI:-8.966 to-0.28). A total of 31 chemical compounds and 178 potential targets for CKZ injection were obtained from the online databases. Molecular docking revealed that most key components and targets could form stable structure.
Conclusion: This systematic review with meta-analysis and network pharmacology demonstrates that CKZ could effectively improve the clinical efficacy and safety in the treatment of COPD. Such efficacy may be related to an anti-inflammatory effect and immunoregulation of CKZ via multiple components, multiple targets and multiple pathways.

Keywords: meta-analysis, network pharmacology, chronic obstructive pulmonary disease, Chuankezhi injection

查看原文本刊更多论文

川楝子注射液治疗慢性阻塞性肺疾病的证据构建：系统综述与网络药理学

目的：慢性阻塞性肺疾病（COPD）是一种发病率、患病率和死亡率都很高的慢性呼吸系统疾病。川贝枇杷膏是治疗慢性阻塞性肺疾病的常用中成药。本研究通过整合荟萃分析和网络药理学，评估了川贝枇杷膏对慢性阻塞性肺病患者的临床疗效，并探讨了潜在的内在机制：通过Web of Science、Cochrane Library和PubMed数据库检索截至2022年11月的随机对照试验（RCTs）进行文献收集，并使用Review Manager 5.4进行数据分析。通过网络药理学方法，进一步分析了化学成分及其靶点以及疾病靶点：结果：共纳入 15 项 RCT，包括 1212 名患者。荟萃分析结果显示，CKZ注射液能显著提高临床有效率（RR=1.25，95% CI：1.14~1.36），其临床优势在于能显著降低急性加重率（RR=0.29，95% CI：0.12~0.70）和COPD评估测试（CAT）评分（MD=- 4.62，95% CI：-8.966~-0.28）。从在线数据库中共获得了31种化合物和178个潜在的CKZ注射靶点。分子对接显示，大多数关键成分和靶点都能形成稳定的结构：本系统综述通过荟萃分析和网络药理学证明，CKZ 可有效提高慢性阻塞性肺疾病治疗的临床疗效和安全性。这种疗效可能与CKZ通过多成分、多靶点和多途径发挥抗炎作用和免疫调节作用有关。关键词：荟萃分析；网络药理学；慢性阻塞性肺疾病；川克止注射液

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Chronic Obstructive Pulmonary Disease RESPIRATORY SYSTEM-

CiteScore

5.10

自引率

10.70%

发文量

372

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals